HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries - GBI Research Reports

HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries

HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries - GBI Research Reports
HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries
Published Oct 03, 2011
98 pages — Published Oct 03, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS therapeutics market. The report analyzes the markets for HIV/AIDS in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage pattern and annual cost of treatment are forecast until 2017 for key geographies in the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

Scope

The scope of this report includes -
- Annualized market data for the HIV therapeutics market from 2002 to 2010, forecast until 2017.
- Analysis of the HIV therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain, and Japan.
- Market characterization of the HIV therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Gilead Sciences Inc, GlaxoSmithKline, Bristol-Myers Squibb, Abbott Laboratories, Merck & Co and Pfizer Inc.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global HIV therapeutics market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Align product portfolio to the markets with high growth potential.
- Develop market entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

  
Source:
Document ID
GBIHC133MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents37
  List of Tables62
  List of Figures82
HIV/AIDS Therapeutics Market to 2017 - Introduction101
  GBI Research Report Guidance101
HIV/AIDS Therapeutics Market to 2017 - Global Overview114
  Disease Overview112
  Market Overview131
  Overview of Recent Research Advancements in HIV/AIDS Therapy141
HIV/AIDS Therapeutics Market to 2017 - Market Characterization1518
  Market Forecasts151
    Branded Versus Generics161
  Annual Cost of Therapy171
  Treatment Usage Patterns182
    Diseased Population202
    Treatment Seeking Population221
    Diagnosis Population232
    Prescription Population251
  Geographical Distribution262
  Drivers and Restraints281
  Market Drivers281
    Increase in Awareness Levels of Disease Progression will Lead to an Increase in Treatment Seeking and Diagnosed Populations281
      Awareness in the US281
      Awareness in Europe281
      Awareness in Japan291
    New Product Launches will Increase Uptake and Drive the Market291
    Increase in Drug Prices will Drive Growth and Lessen the Impact of Generics301
      HIV/AIDS Therapy and Switch to New Drugs301
  Market Restraints301
    Patent Expiries and the Subsequent Entry of Generics will Negatively Impact the Market301
    Social Stigma Associated with HIV/AIDS Leads to Low Treatment Seeking Rate311
    Rigorous and Complex Treatment Regimes Result in Poor Patient Compliance Leading to a Reduction in Drug Volumes321
HIV/AIDS Therapeutics Market to 2017 - The US3310
  Market Forecasts331
  Annual Cost of Therapy341
  Treatment Usage Patterns352
    Diseased Population371
    Treatment Seeking Population382
    Diagnosis Population401
    Prescription Population412
HIV/AIDS Therapeutics Market to 2017 - Top Five European Countries4311
  Market Forecasts432
    Revenue by Country451
  Annual Cost of Therapy461
  Treatment Usage Patterns472
    Diseased Population491
    Treatment Seeking Population501
    Diagnosis Population512
    Prescription Population531
HIV/AIDS Therapeutics Market to 2017 - Japan5410
  Market Forecasts541
  Annual Cost of Therapy552
  Treatment Usage Patterns571
    Diseased Population582
    Treatment Seeking Population601
    Diagnosis Population611
    Prescription Population622
HIV/AIDS Therapeutics Market to 2017 - Pipeline Assessment6410
  Major Classes of Drugs641
    Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)641
    Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)642
    Protease Inhibitors661
    Viral Fusion (or Entry) Inhibitors661
    HIV Integrase Strand Transfer Inhibitors661
    Multi-Class Combination Products661
  Pipeline Overview661
  Strategic Pipeline Assessment671
  HIV/AIDS Therapeutics Pipeline - Pipeline by Clinical Phases of Development671
    HIV/AIDS Therapeutics - Phase III Clinical Pipeline671
    HIV/AIDS Therapeutics - Phase II Clinical Pipeline681
    HIV/AIDS Therapeutics - Phase I Clinical Pipeline691
    HIV/AIDS Therapeutics - Preclinical Pipeline701
    HIV/AIDS Therapeutics - Discovery Clinical Pipeline711
  HIV/AIDS Therapeutics - Pipeline by Mechanism of Action721
  HIV/AIDS Therapeutics - Most Promising Drugs under Clinical Development731
HIV/AIDS Therapeutics Market to 2017 - Competitive Landscape7412
  Major Company Profiles751
    Gilead Sciences, Inc761
      SWOT Analysis761
    GlaxoSmithKline (GSK)771
      SWOT Analysis781
    Bristol-Myers Squibb (BMS)791
      SWOT Analysis801
    Abbott Laboratories811
      SWOT Analysis821
    Merck831
      SWOT Analysis841
    Pfizer851
      SWOT Analysis851
HIV/AIDS Therapeutics Market to 2017 - Licencing and Partnership Deals866
  Overview: Deals by Type and Geography861
  Mergers and Acquisitions871
    Merger of GSK and Pfizer871
    Viral Genetics, Inc. Completed its Acquisition of V-Clip Pharmaceuticals881
  Licensing Agreements881
    Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs891
    Altor BioScience licenses T-cell receptors targeting HIV and hepatitis C from Massachusetts General Hospital891
    Ceragenix Enters into Agreement to License CSA-54 and other Ceragenin Compounds To Biopharmaceutical Company for HIV and STD Applications891
    Microbicide Developer Receives License for Novel HIV Microbicide Candidate from Merck &Co., Inc.901
    Idenix Pharmaceuticals and GlaxoSmithKline have entered into a licensing agreement to co-develop IDX899 for the treatment of HIV infection901
    Myriad Pharmaceuticals, has entered into a Bevirimat acquisition agreement with Panacos Pharmaceuticals Inc901
    Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize New Fixed-Dose Combination of Truvada(R) and TMC278911
    GlaxoSmithKline agrees royalty-free licensing deal for HIV drug911
    Tibotec and Emcure Collaborate on Access to Darunavir for India911
    IPM Reaches Landmark Agreement With Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide911
HIV/AIDS Therapeutics Market to 2017 - Appendix927
  Market Definitions921
  Abbreviations921
  Research Methodology932
    Coverage931
    Secondary Research931
    Primary Research941
  Therapeutic Landscape943
    Epidemiology-based Forecasting951
    Market Size by Geography961
  Geographical Landscape971
  Pipeline Analysis971
  Competitive Landscape971
    Expert Panel Validation971
  Contact Us971
  Disclaimer971
  Sources981

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries" Oct 03, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/HIV-AIDS-Therapeutics-Market-to-2017-Superior-Combination-Therapies-and-Decreasing-Mortality-to-Sustain-Market-Growth-Despite-Major-Patent-Expiries-2115-274>
  
APA:
GBI Research Reports. (2011). HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries Oct 03, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/HIV-AIDS-Therapeutics-Market-to-2017-Superior-Combination-Therapies-and-Decreasing-Mortality-to-Sustain-Market-Growth-Despite-Major-Patent-Expiries-2115-274>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.